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to the cost-effective use of appropriate drugs in managing chronic disease. The project 
highlighted how countries with relevant experience in evidence-informed policy 
making in health care can assist others in strengthening their decision-making systems.
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HEALTH SYSTEM
García Baena I1, García García2 FJ2, Navascues R3, Marti B3
1Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain; 2Subdirector Médico Área 
Médica,, Las Palmas de Gran Canaria, , Spain; 3Medtronic Iberia, Madrid, Spain
OBJECTIVES: The aim of this study was to evaluate costs and beneﬁ ts of diagnosing 
patients with syncope of unknown aetiology with implanted loop recorders compared 
to clinical practice (conventional investigation) of an electrophysiology, from the 
Spanish National Health System perspective. METHODS: Based on an economic 
decision analysis model, the cost-effectiveness study analyses diagnostic yield results 
from clinical practice versus Reveal DX®, with a time horizon of one year. Clinical 
data and resource use was obtained from a randomised controlled trial and expert 
opinion. Cost data was expressed in Euros 2010. a univariate sensitivity analysis was 
carried out to analyze the robustness of the model by modifying the number of out-
patient visits, the costs and the diagnostic yield for both strategies. RESULTS: The 
incremental cost-effectiveness Ratio of Reveal DX® versus conventional investigation 
was c3167 per additional diagnosis, resulting in a conﬁ dence interval of 95% of the 
incremental cost-effectiveness ratio of c2335–c4867 per additional diagnosis made. 
The results of the univariate sensitivity analyses did not change the main results from 
our study. CONCLUSIONS: Reveal DX® in the diagnosis of syncope of unknown 
aetiology after an initial evaluation is a cost-effective strategy compared to conven-
tional diagnosis for the Spanish Health System, since it increases diagnostic yield at a 
reasonable incremental cost.
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OBJECTIVES: In patients with acute coronary syndrome (ACS) undergoing percuta-
neous coronary intervention (PCI), the TRITON-TIMI 38 trial (TT38) demonstrated 
that treatment with prasugrel vs. clopidogrel was associated with signiﬁ cantly reduced 
rates of atherothrombotic events, though with increased risk of bleeding. The aim of 
the analysis was to evaluate the long-term cost-effectiveness of a 12-month treatment 
with prasugrel vs. clopidogrel in the trial population, excluding patients with prior 
transient ischemic attack or stroke, from the perspective of the Spanish health care 
system. METHODS: A Markov model was developed based on risk equations for 
cardiovascular death, myocardial infarction (MI) or stroke, bleeding, and rehospital-
ization, derived from TT38 data (N = 13,608 patients). Cost variables included were 
medication and hospitalizations costs. Hospital readmissions captured during TT38 
in all patients from 8 countries (N = 6705) were assigned to Spanish diagnosis related 
groups, and were modelled to accrue over the life-time horizon. Long term survival 
and quality adjusted survival were estimated for the life-time of each patient. 
RESULTS: At 12 months, a difference in drug costs between prasugrel and clopidogrel 
of +c77 (branded clopidogrel) to +c460 (generic clopidogrel) per patient was partially 
offset by hospital cost savings (−c97 per patient) due principally to reduced rates of 
revascularization. In the longer-term, prasugrel was associated with higher total costs 
(+c11 to +c395 per patient), life expectancy gains of 0.07 years, due primarily to the 
reduced rate of MI, and 0.05 additional QALYs, resulting in incremental costs per 
life-year saved and per QALY gained of c164 to c5718 and c216 to c7540, respec-
tively. Probabilistic sensitivity analysis indicated that prasugrel has a 68% to 72% 
probability of being more cost-effective than clopidogrel at a willingness to pay of 
c30,000 per QALY. CONCLUSIONS: Among ACS-PCI patients, these results showed 
prasugrel to be within the bounds of reasonable cost-effectiveness for Spain in com-
parison with clopidogrel.
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OBJECTIVES: Atrial Fibrillation (AF) is a common cardiac arrhythmia and a signiﬁ -
cant cause of morbidity and mortality worldwide. As it is necessary to maximize value 
from the money spent in health care, an economic evaluation was undertaken to 
compare a new therapy, Dronedarone, in relation to Amiodarone, Sotalol and 
Propafenone already used in the Greek National Health Service (NHS) setting. 
METHODS: An international Markov model was locally adapted. The model reﬂ ects 
the management and the progression of AF patients through different health states in 
the course of their life time, including stroke, post stroke, heart failure (HF), post-HF, 
acute coronary symptom (ACS) post-ACS and death. Clinical and quality of life data 
to populate the model were derived from a variety of relevant clinical studies and 
registries including: ATHENA, AFTER, DIONYSOS, AFFIRM and synthesizing 
analyses undertaken by academic experts. Resource utilization and cost data were 
derived by means of a large and representative panel of local experts, who utilized 
patient data ﬁ les and data which came from a sample of NHS hospitals. Data refer 
to the year 2010 and all outcomes were discounted at a rate of 3.5%. The model is 
probabilistic to account for uncertainly and mean estimates are reported with corre-
sponding uncertainty intervals. RESULTS: Mean total treatment costs were: Droneda-
rone: c12,931 (95%UI: 12,065–c12,495); Amiodarone: c8893 (95%UI: c8685–c9100); 
Sotalol: c6,185 (95%UI: c5901–c6509); Propafenone: c8433 (95%UI: c8229–c8642). 
The incremental cost-per-life-year-gained with Dronedarone versus Amiodarone was: 
c2236 (95%UI: 1897–c2615), versus Sotalol: c2576 (95%UI: c2442–c2822 and 
versus Propafenone: c2718 (95%UI: c2497–c3395). The incremental cost-per-quality-
adjusted-life-year gained with Dronedarone versus Amiodarone was: c3275 (95%UI: 
2730–c3838), versus Sotalol: c4319 (95%UI: c4130–c4510) and versus Propafenone: 
c3138 (95%UI: c2571–c4004). CONCLUSIONS: The newly available treatment 
Dronedarone appears to be a cost-effective alternative to other already existing thera-
pies, used in the management of Atrial Fibrillation patients in the Greek NHS.
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OBJECTIVES: Aortic Stenosis (AS) is a severe cardiovascular condition the treatment 
of which often involves a major operation. For a subgroup of patients medical manage-
ment (MM) is the only treatment option due to procedural risk. a transcatheter aortic 
valve implantation device “CoreValve,” is a novel procedure, is less invasive and 
allows for the implantation of a replacement valve in this patient group. Since informa-
tion is not yet available on key clinical parameters, we modiﬁ ed an existing early stage 
economic model to perform a value of information (VoI) analysis to informing the 
prioritization of future research. METHODS: The underlying model used in the 
analysis is a 10-year Markov model was developed in Microsoft Excel. Treatment 
options were CoreValve and MM with parameters derived from published literature. 
All costs were taken from the most recent published sources. Decrements were applied 
to age-speciﬁ c EQ-5D population norms to generate QALYs. a probabilistic sensitivity 
was used to inform the global Expected Value of Perfect Information (EVPI) calcula-
tion. Deterministic one way analyses were used to select the variable groups and 
individual parameters on which partial EVPI (EVPPI) calculations were performed. 
Annual incident population estimates were derived from information in a large 
national database. RESULTS: Assuming a decision horizon of 10 years, an annual 
incident population of 4052 and a willingness to pay threshold of £30,000 per QALY 
gained the EVPI is £11.3 million. EVPPI estimates were generated for costs, utilities, 
overall survival (MM patients) and treatment effects. Of these, the VoI for baseline 
mortality and long term mortality reduction were greatest (£21,364,000 and 
£8,151,000 respectively). The VoI for all others was negligible CONCLUSIONS: 
Further information on long term survival would have the greatest impact on decision 
uncertainty. Thus, a new clinical trial may not be required and a registry may be more 
appropriate.
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OBJECTIVES: To evaluate the cost-effectiveness of dronedarone for the treatment of 
atrial ﬁ brillation (AF) compared to current antiarrhythmic drugs (AADs), from a UK 
NHS perspective. METHODS: A cost-utility analysis was performed, for which an 
individual patient lifetime discrete event simulation model was constructed. The model 
predicted a patient’s course for a treatment pathway based on the current National 
Institute for Health and Clinical Excellence (NICE) AF guidelines and compared treat-
ment with amiodarone, sotalol and Class 1c agents to dronedarone. The model consisted 
of seven AF-related events; AF recurrence, acute coronary syndromes, stroke, congestive 
heart failure, treatment discontinuation, AF status change and mortality. Between events 
patients resided in four health states; normal sinus rhythm, permanent AF with uncon-
trolled symptoms, permanent AF with controlled symptoms and death. Patient’s baseline 
event risks were estimated from the non-active comparator arm of the ATHENA trial 
then adjusted for treatment effects based on a mixed treatment comparison. Cost data 
were elicited from existing literature and UK reference costs. Quality of life estimates 
were based on data from the AFTER cohort. Cost-effectiveness was measured in cost 
per quality adjusted life-year (QALY) gained. Costs and QALYs were discounted at 
3.5%. One-way and probabilistic sensitivity analyses (PSA) were performed. RESULTS: 
Dronedarone was shown to be cost-effective with incremental cost-effectiveness ratios 
of £2,406 versus amiodarone, £1,911 versus sotalol and £18,737 versus Class 1c 
agents. One-way sensitivity analysis showed that treatment effect on mortality was 
the key driver of cost-effectiveness. PSA results estimated that dronedarone was cost-
effective at an acceptability threshold of £20,000 on 95% of occasions compared to 
amiodarone and sotalol and on 60% of occasions compared to Class 1c agents. 
CONCLUSIONS: The results of this analysis demonstrate that in the UK setting 
dronedarone is a cost-effective treatment of AF compared to current AAD 
treatment.
